China's top health authority reiterated on Thursday that the clinical use of immunotherapy for cancer treatment and public hospitals' subcontracting of departments to private entities are banned. The statement from the National Health and Family Planning Commission came amid a public outcry after the death of a young man who had received such treatment at a military hospital in Beijing. The hospital was found to have outsourced its cancer treatment to a for-profit private company, whose medical treatment was challenged by the patient, 21-year-old Wei Zexi, as ineffective in an online post before his death on April 12. The commission...
↧